RHHBY and CHGCY Related Headlines
Go Back- Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
- Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024
- Roche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics
- Roche navify digital solutions get excellent ratings from healthcare professionals in KLAS Research reports
- New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
- Roche launches next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges
- Roche collaborates with Ibex and Amazon Web Services to accelerate adoption of AI-enabled digital pathology solutions to help improve cancer diagnoses
- FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
- Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare
- Roche launches a new addition to the cobas® connection modules, the CCM Vertical, helping to improve laboratory efficiency
- New opportunities and persistent challenges revealed as organisations attempt more data-driven approaches to healthcare, says new report from Harvard Business Review Analytic Services
- Roche expands long-term alliance with Sysmex
- Roche to showcase next-generation diagnostic solutions at the American Association of Clinical Chemistry 2023 Clinical Lab Expo
- Roche receives FDA clearance for additional Alzheimer's disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making
- New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Roche showcases commitment to advancing innovative diagnostic solutions at WorldLab-EuroMedLab
RHHBY and CHGCY Related Press Releases
Go Back- Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
- Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024
- Roche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics
- Roche navify digital solutions get excellent ratings from healthcare professionals in KLAS Research reports
- New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
- Roche launches next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges
- Roche collaborates with Ibex and Amazon Web Services to accelerate adoption of AI-enabled digital pathology solutions to help improve cancer diagnoses
- FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
- Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare
- Roche launches a new addition to the cobas® connection modules, the CCM Vertical, helping to improve laboratory efficiency
- New opportunities and persistent challenges revealed as organisations attempt more data-driven approaches to healthcare, says new report from Harvard Business Review Analytic Services
- Roche expands long-term alliance with Sysmex
- Roche to showcase next-generation diagnostic solutions at the American Association of Clinical Chemistry 2023 Clinical Lab Expo
- Roche receives FDA clearance for additional Alzheimer's disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making
- New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Roche showcases commitment to advancing innovative diagnostic solutions at WorldLab-EuroMedLab
